From HSA approval to regional distribution, we help medical device and therapeutic innovators navigate regulations, accelerate submissions, and deliver products across Asia-Pacific safely and efficiently.
Comprehensive regulatory solutions tailored for medical device manufacturers, pharmaceutical companies, and healthcare innovators entering APAC markets.
Navigate Singapore HSA approval efficiently — from risk classification to quality systems.
Ensure pharmaceutical and biological product compliance under Singapore's Health Products Act (HPA).
Ongoing vigilance, variation management, APAC scaling support, and continuous compliance assurance.
Expand across Asia-Pacific with secure warehousing, logistics, and regulatory support.
Enable digital health innovation with SaMD classification, lifecycle management, and cybersecurity compliance.
Comprehensive audits, strategic planning, regulatory training, and ongoing advisory services for compliance excellence.
To enable safe, compliant market access for innovative healthcare solutions across Asia-Pacific. We bridge the gap between regulatory complexity and business success, ensuring your products reach patients safely and efficiently.
Maintaining the highest ethical standards in all regulatory processes and client relationships.
Deep regulatory knowledge backed by years of experience in HSA compliance and APAC markets.
Dedicated to your success with personalized attention and unwavering support throughout your journey.
Embracing cutting-edge regulatory approaches and technologies to streamline compliance processes.

A systematic approach to regulatory success, from initial consultation to post-market compliance and APAC expansion.
Comprehensive assessment of your technology, risk classification, and optimal HSA route (Full/Abridged/Expedited pathway).
Building comprehensive dossiers, technical files, and ensuring SHARE portal readiness for seamless submissions.
Direct liaison with HSA, proactive query monitoring, and comprehensive licensing management throughout the process.
Ongoing vigilance, variation management, APAC scaling support, and continuous compliance assurance.
Stay informed with the latest regulatory developments, guidance, and best practices for HSA compliance and APAC market access.
Navigate HSA regulations and enter Singapore's strategic healthcare market with compliance confidence.
Understanding how Quality Management Systems support GN-16 compliance for medical device manufacturers.
Comprehensive guide to HSA's device registration framework, classification requirements, and regulatory pathways.
HSA offers four main registration routes: Full, Abridged, Expedited, and Immediate, depending on device risk, novelty, and prior approvals. Choosing the correct pathway ensures faster review and smoother market entry.
HSA requires death or serious deterioration to be reported within 48 hours, and all other serious adverse events within 15 calendar days. Timely reporting is mandatory to maintain regulatory compliance and market access.
Medical devices are classified under GN-13 into Class A (low risk), B (low–moderate), C (moderate–high), or D (high risk) based on intended use, invasiveness, and duration of contact. Correct classification determines the required documentation, regulatory pathway, and risk management obligations.
Software is considered SaMD if it performs medical functions independently, supports medical decisions, or directly influences patient care without hardware integration. SaMD products must comply with HSA regulations, including risk classification per GN-13, registration requirements per GN-15, and software-specific guidance under GL-04/GL-07 for validation, risk management, and lifecycle management.
Ready to navigate HSA compliance and accelerate your APAC market entry? Let's discuss your regulatory strategy and pathway to success.
Deyun Regulatory Solutions
60 Paya Lebar Road
#06-28 Paya Lebar Square
Singapore 409051
+65 8899 1030
contact@deyunsolutions.com
Monday - Friday: 9:00 AM - 6:00 PM SGT Saturday: 9:00 AM - 1:00 PM SGT